MedTrace Logo

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

NCT02367196 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-08-12

No results posted yet for this study

Summary

CC-90002-ST -001 is an open-label, Phase 1, dose escalation clinical study in subjects with advanced, refractory solid and hematologic cancers.

Conditions

  • Hematologic Neoplasms

Interventions

DRUG

CC-90002

DRUG

Rituximab

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Michael Burgess, MD, PhD · Celgene

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-12
Primary Completion
2020-12-24
Completion
2020-12-24

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02367196 on ClinicalTrials.gov